Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2009-05-15
2010-11-16
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S152100, C424S153100, C424S172100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750
Reexamination Certificate
active
07833530
ABSTRACT:
The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for such antibodies and binding fragments thereof and to methods of therapeutic use thereof.
REFERENCES:
patent: 5667988 (1997-09-01), Barbas et al.
patent: 7744888 (2010-06-01), Lin et al.
patent: 2002/0031508 (2002-03-01), Wagner et al.
patent: 2002/0086014 (2002-07-01), Korman et al.
patent: 2003/0018181 (2003-01-01), Larsen et al.
patent: 2004/0001839 (2004-01-01), Levanon et al.
patent: 2004/0002450 (2004-01-01), Lazarovits et al.
patent: 2004/0214272 (2004-10-01), La Rosa et al.
patent: 2005/0069955 (2005-03-01), Plaksin et al.
patent: 2006/0286112 (2006-12-01), Kellermann et al.
patent: 2007/0020624 (2007-01-01), Rubenfield et al.
patent: 2007/0160601 (2007-07-01), Widom et al.
patent: 2008/0019984 (2008-01-01), Shusta et al.
Hirata et al., “Human P-selectin glycoprotein ligand-1 (PSGL-1) interacts with the skin-associated chemokine CCL27 via sulfated tyrosines at the PSGL-1 amino terminus,”J. Biol. Chem., (Issue of Dec. 10, 2004) vol. 279, No. 50, pp. 51775-51782.
Inoue, et al., “Blockade of PSGL-1 attenuates DC14+ monocytic cell recruitment in Intestinal mucosa and ameliorates ileitis in SAMP1/Yit mice,”Journal of Leukocyte Biology, (Mar. 2005) vol. 77, pp. 287-295.
Li et al., “Visualization of P-selectin Glycoprotein Ligand-1 as a Highly Extended Molecule and Mapping of Protein Epitopes for Monoclonal Antibodies,”The Journal of Biological Chemistry, vol. 271, No. 11, (Issue of Mar. 15, 1996) pp. 6342-6348.
Marini et al., “TNF-α neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis,”PNAS, vol. 100, No. 14, (Jul. 8, 2003) pp. 8366-8371.
Moore et al., “P-Selectin Glycoprotein Ligand-1 Mediates Rolling of Human Neutorphils on P-Selectin,”J. Cell. Biol., vol. 128, No. 4 (Feb. 1995) pp. 661-671.
Rivera-Nieves et al., “Critical role of endothelial P-selectin glycoprotein ligand 1 in chronic murine ileitis”,The Journal of Experimental Medicine, vol, 203, No, 4, (Apr. 17, 2006) pp, 907-917.
Swers, “Isolation and Engineering of a High Affinity Antibody Against P-selectin Glycoprotein Ligand-1 (PSGL-1),” Ph.D. Thesis,Department of Engineering at Massachusetts Institute of Technology, (Feb. 18, 2005) pp. 1-96.
Swers et al., “A high affinity human antibody antagonist of P-selectin mediated rolling,”Biochemical and Biophysical Research Communications, vol. 350, (Aug. 12, 2006) pp. 508-513.
Thatte et al., “Binding of function-blocking mAbs to mouse and human P-selectin glycoprotein ligand-1 peptides with and without tyrosine sulfation,”Journal of Leukocyte Biology, vol. 72, (Sep. 2002) pp. 470-477.
Veerman et al., “Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs,”Nature Immunology, vol, 8, No. 5 (May 2007) pp. 532-539.
PCT Search Report, PCT/US2009/044188, Dec. 4, 2009.
Alvarez Richard
Rollins Scott
Dunlap Codding P.C.
Gambel Phillip
Selexys Pharmaceuticals Corporation
LandOfFree
Methods of inhibiting the PSGL-1-mediated adhesion and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting the PSGL-1-mediated adhesion and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting the PSGL-1-mediated adhesion and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248370